

/Where ideas thrive

Cambridge Enterprise

BIO2023 5th – 8th June 2023

Phil Elstob

Commercialisation Director & Deputy Head of Life Science Phil.Elstob@enterprise.cam.ac.uk


Katja Kostelnik

Commercialisation Manager Katja.Kostelnik@enterprise.cam.ac.uk Cambridge Enterprise is uniquely positioned with access to ground-breaking technologies and solutions from the University of Cambridge.

Our team partners these with organisations and investors around the world to develop products and services that create positive social change.

5日日 UNIVERSITY OF 5日日 CAMBRIDGE enterprise

Our performance, 2020-21





Investment in numbers

Novel divinylpyrimidine (DVP) chemistry for antibody-drug conjugation





Novel divinylpyrimidine (DVP) chemistry for antibody-drug conjugation

-1

0

enterprise






UNIVERSITY OF CAMBRIDGE enterprise


-20-

Novel divinylpyrimidine (DVP) chemistry for antibody-drug conjugation

Trastuzumab-DVP-MMAE



- Vehicle
- --- Tras 10 mg/kg
- --- Cleavable 1 mg/kg
- --- Cleavable 10 mg/kg
- --- Cleavable 20 mg/kg
- Non-cleavable 1 mg/kg
- ---- Non-cleavable 10 mg/kg
- Non-cleavable 20 mg/kg



- native antibody
- controlled DAR of 4
- no retro-Michael addition
- on-antibody functionalisation